Literature DB >> 4055040

Clinical experience of cefotaxime in infections caused by gram-positive pathogens.

D Bassetti, M Solbiati, G Fraizzoli.   

Abstract

We studied the activity of cefotaxime both microbiologically and clinically. 138 blood cultures positive for gram-positive cocci were evaluated (90 strains of Staphylococcus aureus, 25 of Streptococcus faecalis, 13 of Streptococcus alpha and ten of Streptococcus mutans). Cefotaxime showed good activity against all strains with the exception of S. mutans, of which only 30% were sensitive. Ten cases of gram-positive infections were studied clinically: six sepsis cases and one endocarditis case due to S. aureus, two sepsis cases caused by Streptococcus alpha and one Enterococcus endocarditis case. Therapy was successful in nine; the S. aureus endocarditis failed. The local and general tolerance of cefotaxime was good.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055040     DOI: 10.1007/BF01644230

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

2.  Cefotaxime in the treatment of septicaemia and endocarditis.

Authors:  M Armengaud; P Massip; J Aubertin; J M Ragnaud; A Bertrand; G Lepeu
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

3.  Clinical experience with cefotaxime in the treatment of patients with bacteremia.

Authors:  B R Meyers
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

4.  Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.

Authors:  C Watanakunakorn; J C Tisone
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

5.  Activity of ten cephalosporins on biomass of methicillin-susceptible and -resistant Staphylococcus aureus.

Authors:  E Yourassowsky; M P Van der Linden; M J Lismont; F Crokaert
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

6.  Comparison of activity and beta-lactamase stability of cefotaxime with those of six other cephalosporins.

Authors:  R P Mouton; G P Bongaerts; M van Gestel
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors:  C Watanakunakorn
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

8.  Clinical efficacy of cefotaxime in serious infections.

Authors:  P H Karakusis; J M Feczko; L J Goodman; D M Hanlon; A A Harris; S Levin; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

9.  Therapy of staphylococcal septicaemia in compromised hosts.

Authors:  C O Solberg; A Digranes; T Kalager
Journal:  Scand J Infect Dis Suppl       Date:  1983

10.  Comparative in vitro activity of cefotaxime (HR 756).

Authors:  G Peters; G Pulverer
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.